Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

Publisher： Karger

E-ISSN： 1421-9832|222|3|250-255

ISSN： 1018-8665

Source： Dermatology, Vol.222, Iss.3, 2011-04, pp. : 250-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis

By  

Dermatology, Vol. 228, Iss. 1, 2014-01 ,pp. : 78-85

Karger

Access to resources Recommend Favorite

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

By  

Dermatology, Vol. 221, Iss. 2, 2010-07 ,pp. : 172-178

Karger

Access to resources Recommend Favorite

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

By  

Dermatology, Vol. 230, Iss. 1, 2015-01 ,pp. : 46-54

Karger

Access to resources Recommend Favorite

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

By  

Dermatology, Vol. 216, Iss. 3, 2008-01 ,pp. : 260-270

Karger

Access to resources Recommend Favorite

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

By  

Dermatology, Vol. 219, Iss. 3, 2009-09 ,pp. : 239-249

Karger

Access to resources Recommend Favorite